SCHEMBL26091668

SCHEMBL26091668

CC(C(=O)N1CCN(c2ccc(F)cc2)c2cc(F)ccc21)N1CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.39
▸ AAK1 Q2M2I8 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ P2RX7 Q99572 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ AVPR1A P37288 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ RECQL P46063 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26088865 0.94 ALDH1A1 (0.38) AAK1MEN1KMT2AMAPTLMNA
SCHEMBL26089277 0.90 KMT2A (0.43) AKR1C3MEN1KMT2AMAPTP2RX7
SCHEMBL30379848 0.90 KMT2A (0.43) AKR1C3MEN1KMT2AMAPTP2RX7
SCHEMBL26088765 0.90 SLC6A2 (0.43) MEN1KMT2AMAPTLMNATSHR
SCHEMBL26091655 0.89 SLC6A2 (0.45) MEN1KMT2ALMNASMN1; SMN2AVPR1A
SCHEMBL26092300 0.88 SIGMAR1 (0.45) MEN1KMT2AMAPTLMNATSHR
SCHEMBL26089204 0.83 CHRNB2 (0.44) MEN1KMT2AMAPTLMNATSHR
SCHEMBL26088697 0.82 CHRNB2 (0.46) MEN1KMT2AMAPTLMNATSHR
SCHEMBL26088510 0.81 SIGMAR1 (0.44) MEN1KMT2AMAPTLMNATSHR
SCHEMBL29220785 0.81 AVPR1A (0.38) MAPTLMNATSHRSMN1; SMN2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US claimed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP claimed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 AKR1C3 2384/4885AAK1 2251/4885MEN1 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback